New drug aims to keep aggressive cancer at bay after chemo
NCT ID NCT06926634
Summary
This study is testing if a drug called zanzalintinib can help keep aggressive neuroendocrine tumors from growing after patients finish their initial chemotherapy. It is for adults whose cancer has stopped growing or shrunk after chemo. The main goal is to see if this maintenance treatment can extend the time before the cancer starts growing again.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE NEUROENDOCRINE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic - Rochester
NOT_YET_RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-••••
Contact
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.